Abstract
It was shown before that the soluble form of VEGFR-1 (sVEGFR-1) is present in serum of pregnant women. The aim of the present study was to investigate the presence of this endogenous vascular endothelial growth factor-A (VEGF-A) antagonist in human serum in more detail. sVEGFR-1 was detected in human serum and plasma from normal healthy male and female donors by ELISA. sVEGFR-1 levels ranged from non-detectable up to 440 pg/ml, with no significant difference between male and female donors. In addition, vein endothelial cells (ECs) from an intact vascular bed, the umbilical cord, were shown to secrete sVEGFR-1. Furthermore, human peripheral blood monocytes, a non-EC type expressing VEGFR-1, were shown to contribute to the sVEGFR-1 detectable in human serum and plasma for the first time. EC- and monocyte-derived sVEGFR-1 proved capable of inhibiting the VEGF-induced proliferation and migration of ECs in vitro. Finally, secretion of sVEGFR-1 was increased by the angiogenic factor basic fibroblast growth factor (bFGF) in human ECs and was also enhanced in lipopolysaccharide-activated human monocytes. In human umbilical vein endothelial cells, both the membrane-bound and the sVEGFR-1 seem to be equally regulated on the mRNA as well as the protein level. The presence of an sVEGFR-1 in human serum and plasma of normal male and female donors strongly suggests that it plays an important role as a naturally occurring VEGF antagonist in the regulation and availability of VEGF-mediated biological activities in vivo.
Similar content being viewed by others
References
Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992; 359: 845–8.
Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480–7.
Fava RA, Olson NJ, Spencer-Green G et al. Vascular permeability factor/endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 1994; 180: 341–6.
Detmar M, Brown LF, Claffey KP et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med 1994; 180: 1141–6.
Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13: 9–22.
Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999; 9: 211–20.
Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435–9.
Fong G-H, Rossant J, Gertsenstein M, Breitman ML. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66–70.
de Vries C, Escobedo JA, Ueno H et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989–91.
Terman BI, Dougher-Vermazen M, Carrion ME et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579–86.
Borg JP, Barleon B, Marmé D, Birnbaum D. The family of VEGF tyrosine kinase receptors. In Lonai P (ed): Towards a Molecular Analysis of Mammalian Development. Reading, UK: Harwood Academic 1996.
Barleon B, Sozzani S, Zhou D et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336–43.
Takagi H, King GL, Aiello LP. Identification and characterization of vascular endothelial growth factor receptor (FLT) in bovine retinal pericytes. Diabetes 1996; 45: 1016–23.
Clark DE, Smith SK, He Y et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 1998; 59: 1540–8.
Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 1996; 226: 324–8.
Wang G, Thomas KA. Purification and characterization of a functional soluble fibroblast growth factor receptor 1. Biochem Biophys Res Commun 1994; 203: 1781.
Yabkowitz R, Meyer S, Yanagihara D et al. Regulation of Tie receptor expression on human endothelial cells by protein kinase C-mediated release of soluble Tie. Blood 1997; 90: 706–15.
Tiesman J, Hart CE. Identification of a soluble receptor for platelet-derived growth factor in cell-conditioned medium and human plasma. J Biol Chem 1993; 268: 9621–7.
Günther N, Betzel C, Weber W. The secreted form of the epidermal growth factor receptor. Characterization and crystallization of the receptor-ligand complex. J Biol Chem 1990; 265: 22082–5.
Yabkowitz R, Meyer S, Black T et al. Inflammatory cytokines and vascular endothelial growth factor stimulates the release of soluble TIE receptor from human endothelial cells via metalloproteinase activation. Blood 1999; 93: 1969–79.
Shibuya M, Yamaguchi S, Yamane A et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990; 5: 519–24.
Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993; 90: 10705–9.
Sozzani SW, Luini W, Molino M et al. The signal transduction pathway involved in the migration induced by a monocyte chemotactic cytokine. J Immunol 1991; 147: 2215–21.
Fiebig B, Jäger B, Schöllmann C et al. Synthesis and assembly of a functionally active human vascular endothelial growth factor homodimers in insect cells. Eur J Biochem 1992; 211: 19–26.
Hunter W, Greenwood FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 1962; 194: 495–6.
Barleon B, Totzke F, Herzog C et al. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the VEGF receptor FLT-1. J Biol Chem 1997; 272: 10382–8.
Barleon B, Siemeister G, Martiny-Baron G et al. Vascular endothelial growth factor upregulates its receptor FLT-1 and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res 1997; 57: 5421–5.
Barleon B, Hauser S, Schöllmann C et al. Differential expression of the two VEGF receptors flt and KDR in placenta and vascular endothelial cells. J Cell Biochem 1994; 54: 56–66.
Leavesley DI, Schwartz MA, Rosenfeld M, Cheresh DA. Integrin β1-and β3-mediated endothelial cell migration is triggered through distinct signaling mechanisms. J Cell Biol 1993; 121: 163–70.
Barleon B, Weich HA, Marmé D. Differential regulation of the two VEGF receptor genes Flt-1 and KDR by cytokines and growth factors. J Cell Biochem 1994; (Suppl 18A): EZ200 (Abstr).
Sunderkötter C, Steinbrink K, Goebeler M et al. Macrophages and angiogenesis. J Leuk Biol 1994; 55: 410–22.
Hornig C, Behn T, Bartsch W et al. Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA. J Immunol Meth 1999; 226: 169–77.
He Y, Smith SK, Day KA et al. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 1999; 13: 537–45.
Banks RE, Forbes MA, Searles J et al. Evidence for the existence of a novel pregnancy-associated soluble variant of the vascular endothelial growth factor receptor, Flt-1. Mol Hum Reprod 1998; 4: 377–86.
Heaney ML, Golde DW. Soluble cytokine receptors. Blood 1996; 87: 847–57.
Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: Generation and biological function. Biochem J 1994; 300: 281–90.
Aiello LP, Pierce EA, Foley ED et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995; 92: 10457–61.
Lin P, Sankar S, Shan S et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor. Cell Growth Differ 1998; 9: 49–58.
Kong HL, Hecht D, Song W et al. Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. Hum Gene Ther 1998; 10: 823–33.
Goldman CK, Kendall RL, Cabrera G et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc Natl Acad Sci USA 1998; 95: 8795–800.
Siemeister G, Schirner M, Weindel K et al. Two independent mechanisms essential for tumor growth angiogenesis: Inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. Cancer Res 1999; 59: 3185–91.
Kremer C, Breier G, Risau W, Plate KH. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res 1997; 57: 3852–9.
Pepper MS, Mandriota SJ. Regulation of vascular endothelial growth factor receptor-2 (Flk-1) expression in vascular endothelial cells. Exp Cell Res 1998; 241: 414–25.
Koch AE, Polverini PJ, Leibovich SJ. Induction of neovascularization by activated human monocytes. J Leuk Biol 1986; 39: 233–8.
Polverini PJ, Cotrans RS, Gimbrone MA Jr, Unanue EM. Activated macrophages induce vascular proliferation. Nature 1997; 269: 804–6.
Inoue T, Kibata K, Suzuki M et al. Identification of a vascular endothelial growth factor (VEGF) antagonist, sFlt-1, from a human hematopoietic cell line NALM-16. FEBS Lett 2000; 469: 14–8.
Ratajczak MZ, Ratajczak J, Machalinski B et al. Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PlGF) in regulating human haemopoietic cell growth. Br J Haematol 1998; 103: 969–79.
Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996; 2: 1096–103.
Katoh O, Tauchi H, Kawaishi K et al. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 1995; 55: 5687–92.
Hiratsuka S, Minowa O, Kuno J et al. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998; 95: 9349–54.
Harris AL, Reusch P, Barleon B et al. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 2001; 7: 1992–7.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barleon, B., Reusch, P., Totzke, F. et al. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 4, 143–154 (2001). https://doi.org/10.1023/A:1012245307884
Issue Date:
DOI: https://doi.org/10.1023/A:1012245307884